Back to PHM.MCView Full Landscape
Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
2
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
10 competitors in Influenza
MRNAmRNA Flu vaccine
BNTXInfluenza and COVID-19 Combination A
Phase 3SNYA/H1N1 pandemic influenza vaccine (non- adjuvanted)
Phase 3NVSSurface Antigen, Inactivated, Adjuvanted, Influenza Vaccine, Formulation 2007-2008
Phase 2BNTXInvestigational COVID-19 Vaccine
Phase 2Drug Information
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Regulatory Approvals
EMA6/3/2024
Fluenz
Fluenz is indicated for active immunisation for the prevention of influenza disease in children and adolescents from 2 years to less than 18 years of age.Fluenz should be used in accordance with official recommendations.
View on EMAEMA1/27/2011
Fluenz
Prophylaxis of influenza in individuals 24 months to less than 18 years of age. The use of Fluenz should be based on official recommendations.
View on EMADrug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts